Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06506513

Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease Behavior Motor Activity

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cliniques universitaires Saint-Luc, Brussels, Belgium

Loading trial locations.

About this study

In this monocenter interventional study, we will assess the impact of physical activity on muscle fat content and liver disease severity in MASLD as well as the mechanisms mediating the potential beneficial effects of exercise.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • confirmed MASLD at abdominal imaging
  • confirmed excessive muscle lipid content at imaging
  • stable weight

Exclusion criteria

  • severe comorbidities including active malignancies, neuromuscular degenerative diseases
  • contraindications to physical activity
  • excessive alcohol consumption

Treatment and study plan

High-intensity interval training

Other

High-intensity interval training

Moderate intensity exercise training

Other

Moderate intensity exercise training

Low intensity exercise training

Other

Low intensity exercise training

Primary outcomes

  1. the impact of physical activity on muscle and liver phenotypes

    Time frame: every four weeks from baseline till study completion

    the investigators will assess at baseline and every four weeks till study completion the impact of intervention on liver phenotype assessed by transient elastography and muscle phenotype assessed by MRI

Study contacts

Contact information is provided by the study sponsor or research team.

Guillaume Henin, MD, PhD student

CONTACT

[email protected]

0032494312548

Nicolas Lanthier, MD, PhD

CONTACT

[email protected]

003227647089

Sponsors and collaborators

Lead sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Other

Collaborators

  • Concerted Research Action
  • Fonds National de la Recherche Scientifique

Registry information

Official study title

Targeting Myosteatosis Though Physical Exercise to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

Acronym: MYO-MASLD

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jul 17, 2024
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.